1-10 of 10
Akio Mizutani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT110: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts

Noboru Yamamoto, Takafumi Koyama, Yuki Katsuya, Jun Sato, Toshio Shimizu, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Eiji Takahara, Shingo Shoji, Akio Mizutani, Daisuke Morishita, Robert W. Oda, Hiroshi Miyake, Kan Yonemori
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT110.
https://doi.org/10.1158/1538-7445.AM2024-CT110
Published: 05 April 2024
View articletitled, Abstract CT110: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts
Journal Articles

Abstract CT115: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort

Hisayuki Yokoyama, Noriko Fukuhara, Koji Ando, Hiroatsu Iida, Takahiro Yamauchi, Suguru Fukuhara, Koji Izutsu, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Eiji Takahara, Shingo Shoji, Akio Mizutani, Daisuke Morishita, Robert W. Oda, Hiroshi Miyake, Noboru Yamamoto
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT115.
https://doi.org/10.1158/1538-7445.AM2024-CT115
Published: 05 April 2024
View articletitled, Abstract CT115: A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort
Journal Articles

Abstract 1233: Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma

Yasumichi Inoue, Koki Hikami, Shunsuke Ebara, Midori Sugiyama, Robert Oda, Akio Mizutani, Misaki Yoshida, Hiroko Yamakawa, Shigehiro Yagishita, Akinobu Hamada, Hidetoshi Hayashi, Masaki Ri, Shinsuke Iida, Daisuke Morishita
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1233.
https://doi.org/10.1158/1538-7445.AM2024-1233
Published: 22 March 2024
View articletitled, Abstract 1233: Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma
Journal Articles

Abstract 3301: Translational research of CDK12/13 inhibitor, CTX-439, informing clinical trial strategy

Hiroko Yamakawa, Shunsuke Ebara, Akio Mizutani, Misaki Yoshida, Midori Sugiyama, Koji Yamamoto, Daisuke Komura, Miwako Kakiuchi, Shumpei Ishikawa, Kosuke Yusa, Daisuke Morishita
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3301.
https://doi.org/10.1158/1538-7445.AM2024-3301
Published: 22 March 2024
View articletitled, Abstract 3301: Translational research of CDK12/13 inhibitor, CTX-439, informing clinical trial strategy
Journal Articles

Abstract 2081: Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, Hirokazu Tozaki, Yoshihiko Satoh, Takuto Mori, June Takeda, Hideki Makishima, Masahiro Nakagawa, Yasuhito Nannya, Seishi Ogawa
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2081.
https://doi.org/10.1158/1538-7445.AM2024-2081
Published: 22 March 2024
View articletitled, Abstract 2081: Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials
Journal Articles

Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor

Hiroko Yamakawa, Akio Mizutani, Yasuyoshi Arikawa, Shunsuke Ebara, Yoshihiko Satoh, Daisuke Morishita
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5485.
https://doi.org/10.1158/1538-7445.AM2022-5485
Published: 15 June 2022
View articletitled, Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
Journal Articles

Abstract 5389: Exploring potential predictive biomarkers for the responsiveness to CTX-712 by in vivo drug sensitivity analysis on PDX models

Daisuke Morishita, Shigehiro Yagishita, Akio Mizutani, Hiroko Yamakawa, Shunsuke Ebara, Akinobu Hamada
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5389.
https://doi.org/10.1158/1538-7445.AM2022-5389
Published: 15 June 2022
View articletitled, Abstract 5389: Exploring potential predictive biomarkers for the responsiveness to CTX-712 by in vivo drug sensitivity analysis on PDX models
Journal Articles

Abstract 5494: CTX-712, a novel splicing modulator targeting myeloid neoplasms

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, Takuto Mori, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5494.
https://doi.org/10.1158/1538-7445.AM2022-5494
Published: 15 June 2022
View articletitled, Abstract 5494: CTX-712, a novel splicing modulator targeting myeloid neoplasms
Journal Articles

LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B

Shinji Takagi, Yoshinori Ishikawa, Akio Mizutani, Shinji Iwasaki, Satoru Matsumoto, Yusuke Kamada, Toshiyuki Nomura, Kazuhide Nakamura
Journal: Cancer Research
Cancer Res (2017) 77 (17): 4652–4662.
https://doi.org/10.1158/0008-5472.CAN-16-3502
Published: 31 August 2017
View articletitled, LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B
Open the PDF for LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B in another window
Includes: Supplementary data
Journal Articles

Abstract 2520: TAK-733, a novel MEK1/2 inhibitor, inhibits tumor angiogenesis without affecting vascular permeability

Hori Akira, Shuntarou Tsuchiya, Yuichi Kakoi, Akio Mizutani, Patrick Vincent
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 2520.
https://doi.org/10.1158/1538-7445.AM10-2520
Published: 15 April 2010
View articletitled, Abstract 2520: TAK-733, a novel MEK1/2 inhibitor, inhibits tumor angiogenesis without affecting vascular permeability